文献速递细胞病理与分子病理神经与头颈病理

头颈细胞病理WHO报告系统与米兰唾液腺报告系统的对比分析

Comparative analysis of the World Health Organization Reporting System for Head and Neck Cytopathology and the Milan System for Reporting Salivary Gland Cytopathology.
PubMed 文献 · Cancer Cytopathol · 2025-01-01

该研究对比了WHO头颈细胞病理报告系统与米兰唾液腺细胞病理报告系统(MSRSGC),基于Institut Curie 1954-2022年2218例唾液腺细针穿刺样本(1356例有组织学随访)。两系统均能有效识别恶性,WHO系统将非肿瘤和良性肿瘤合并为「良性」类别简化了报告并减少变异,但可能掩盖两者临床差异。

要点

  • 两系统诊断性能高:敏感性93.3%、特异性93.9%、阳性预测值94.2%、阴性预测值92.9%。
  • MSRSGC中良性肿瘤ROM为4.3%,非肿瘤ROM为16.8%,WHO合并后良性类别ROM为7.1%。
  • WHO合并良性类别简化报告但可能掩盖非肿瘤与良性肿瘤的临床差异。

核心结论

  • 两种报告系统均能有效识别恶性。
  • WHO系统将非肿瘤和良性肿瘤合并为良性类别,简化报告并减少变异,但可能掩盖临床显著差异。

研究设计与样本

  • 回顾性对比分析,纳入Institut Curie(巴黎)1954-2022年2218例唾液腺细针穿刺样本,其中1356例有组织学随访。
  • 样本分别按MSRSGC和WHO系统分类,计算各类别恶性风险(ROM)并评估诊断性能指标。

主要发现

  • MSRSGC的ROM:ND 50%(n=2);NN 16.8%(n=149);AUS无病例;BN 4.3%(n=514);SUMP 50%(n=2);SM 56.1%(n=66);M 98.2%(n=623)。
  • WHO系统的ROM:不足/不满意/无诊断50%(n=2);良性7.1%(n=663);不典型无病例;NUMP 50%(n=2);SM 56.1%(n=66);M 98.2%(n=623)。
  • WHO良性类别合并NN和BN,将NN较高ROM(16.8%)和BN较低ROM(4.3%)平衡为7.1%。
  • 排除ND和SUMP/NUMP类别后,两系统诊断性能:敏感性93.3%、特异性93.9%、阳性预测值94.2%、阴性预测值92.9%。

临床怎么用

  • 两系统均可用于唾液腺细针穿刺的恶性风险分层。
  • WHO系统合并良性类别可简化报告流程,但需注意可能掩盖非肿瘤与良性肿瘤的临床差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A comparative analysis of the International Academy of Cytology-International Agency for Research on Cancer-World Health Organization Reporting System for Head and Neck Cytopathology (WHO) and the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was performed. METHODS: A total of 2218 salivary gland fine-needle aspiration samples collected at the Institut Curie, Paris (1954-2022) were evaluated, with 1356 having histological follow-up. Samples were classified according to the MSRSGC (nondiagnostic [ND], nonneoplastic [NN], atypia of undetermined significance [AUS], benign neoplasm [BN], salivary gland neoplasm of uncertain malignant potential [SUMP], suspicious for malignancy [SM], and malignant [M]) and the WHO system (insufficient/inadequate/nondiagnostic, benign, atypical, neoplasm of uncertain malignant potential [NUMP], suspicious for malignancy [SM], and malignant [M]). The risk of malignancy (ROM) was calculated for each category, and diagnostic performance metrics were assessed. RESULTS: In the MSRSGC, the ROM was ND, 50% (n = 2); NN, 16.8% (n = 149); AUS (no cases); BN, 4.3% (n = 514); SUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). In the WHO system, the ROM was insufficient/inadequate/nondiagnostic, 50% (n = 2); benign, 7.1% (n = 663); atypical (no cases); NUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). The WHO's "benign" category, which combines NN and BN, balanced the NN's higher ROM (16.8%) and BN's lower ROM (4.3%) into 7.1%. Excluding the ND and SUMP/NUMP categories, both systems demonstrated high diagnostic performance: sensitivity, 93.3%; specificity, 93.9%; positive predictive value, 94.2%; and negative predictive value, 92.9%. CONCLUSIONS: Both systems effectively identify malignancy. The WHO system's merger of NN and BN into the benign category streamlines reporting and reduces variability, although it may mask clinically significant differences between nonneoplastic and benign neoplastic lesions.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Kowalewski A, Borowczak J, Choussy O, et al. Comparative analysis of the World Health Organization Reporting System for Head and Neck Cytopathology and the Milan System for Reporting Salivary Gland Cytopathology. Cancer Cytopathol. 2025. PMID: 40853710. doi:10.1002/cncy.70041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。